LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $97.60 Consensus PT from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given an average recommendation of “Hold” by the five brokerages that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $97.60.

LMAT has been the topic of several research analyst reports. Barrington Research upgraded shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald upped their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th.

LeMaitre Vascular Stock Down 2.1%

Shares of LeMaitre Vascular stock opened at $92.29 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The company has a 50-day moving average of $89.69 and a 200 day moving average of $86.06. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 44.80, a PEG ratio of 2.42 and a beta of 0.79. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. The company had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 38.83%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the transaction, the director owned 2,916 shares of the company’s stock, valued at approximately $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 in the last 90 days. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust grew its stake in shares of LeMaitre Vascular by 1,913.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 287 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter valued at approximately $26,000. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular during the 1st quarter valued at approximately $36,000. Geneos Wealth Management Inc. grew its stake in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $47,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.